Injecting drugs by a tube from appendix stump to colon may be a good method for dealing with refractory ulcerative colitis

Medical Hypotheses

Volumn 74, Issue 4, 2010, Pages 631-633

  Xu, Xiangshang ^a   Cao, Zhixin ^a   Li, Xiaolan ^a   Tao, Deding ^a   Hu, Junbo ^a   Yang, Chuanyong ^a   Gong, Jianping ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; BASILIXIMAB; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; INFLIXIMAB; PLACEBO; TINIDAZOLE; VISILIZUMAB;

ABDOMINAL CRAMP; APPENDECTOMY; APPENDIX STUMP TO COLON TUBE DRUG ADMINISTRATION; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DYSPNEA; ELECTIVE SURGERY; FLATULENCE; GASTRITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; ILEOANAL ANASTOMOSIS; INFECTION; INSULIN RESISTANCE; LAPAROSCOPIC SURGERY; LETHARGY; LEUKOPENIA; LOW BACK PAIN; NAUSEA; NEOPLASM; NEUTROPENIA; NONHUMAN; OSTEOPOROSIS; PANCYTOPENIA; PARESTHESIA; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; REMISSION; STOMACH ULCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, TOPICAL; APPENDECTOMY; APPENDIX; CLINICAL PROTOCOLS; COLITIS, ULCERATIVE; COLON; GASTROINTESTINAL HEMORRHAGE; HUMANS; INJECTIONS; INJECTIONS, INTRAVENOUS; RECTUM; RECURRENCE;

EID: 77649341801     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.10.042     Document Type: Article

References (30)

1. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol 19 Suppl. A (2005) 5-36
2. Kornbluth A., and Sachar D.B. Practice parameters committee of the American college of gastroenterology. Ulcerative colitis practice guidelines in adults (update): American college of gastroenterology, practice parameters committee. Am J Gastroenterol 99 (2004) 1371-1385
3. Guthrie E., Jackson J., Shaffer J., Thompson D., Tomenson B., and Creed F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. Am J Gastroenterol 97 (2002) 1994-1999
4. Bassi A., Dodd S., Williamson P., and Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 53 (2004) 1471-1478
5. Cima R.R., and Pemberton J.H. Medical and surgical management of chronic ulcerative colitis. Arch Surg 140 (2005) 300-310
6. Travis S.P.L., Stange E.F., Le'mann M., et al. For the European Crohn's and colitis organisation (ECCO). European evidence-based consensus on the management of ulcerative colitis current management. J Crohn's Colitis 2 (2008) 24-62
7. Kesisoglou F., and Zimmermann E.M. Novel drug delivery strategies for the treatment of inflammatory bowel disease. Expert Opin Drug Deliv 2 (2005) 451-463
8. Marteau P., Probert C.S., Lindgren S., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomized, double blind, placebo controlled study. Gut 54 (2005) 960-965
9. Carter M.J., Lobo A.J., and Travis S.P. IBD section BSoG. Guidelines for the management of inflammatory bowel disease in adults. Gut 53 Suppl. 5 (2004) V1-16
10. Lichtenstein G.R., Abreu M.T., Cohen R., and Tremaine W. American gastroenterological association. American gastroenterological association institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 (2006) 940-987
11. Lichtger S., Present D.H., Konblunth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330 (1994) 1841-1845
12. Actis G., Fadda M., David E., and Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporine: a long term retrospective cohort study. BMC Gastroenterol 7 (2007) 13
13. Arts J.M., Dhaens G.M., Zeegers M.M., et al. Long-term outcome of treatment with intravenous cyclosporine in patients with severe ulcerative colitis. Inflamm Bowel Dis 10 (2004) 73-78
14. Campbell S., Travis S., and Jewell D. Ciclosporine use in acute ulcerative colitis: along-term experience. Eur J Gastroenterol Hepatol 17 (2005) 79-84
15. Cohen R.D. How should we treat severe acute steroid-refractory ulcerative colitis?. Inflamm Bowel Dis 15 (2009) 150-151
16. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
17. Van Den Brande J.M., Peppelenbosch M.P., and Van Deventer S.J. Treating Crohn's disease by inducing T lymphocyte cell death. Ann N Y Acad Sci 973 (2002) 166-180
18. Van den Brande J.M., Braat H., Van den Brink G.R., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124 (2003) 1774-1785
19. Creed T.J., Norman M.R., Probert C.S., et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistent ulcerative colitis. Aliment Pharm Ther 18 (2003) 65-75
20. Hare N.C., Arnott I.D., and Satsangi J. Expert Rev Gastroenterol Hepatol 2 (2008) 357-370
21. Carpenter P.A., Pavlovic S., Tso J.Y., et al. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human cells. J Immunol 165 (2000) 6205-6213
22. Plevy S., Salzberg B., Van Assche G., et al. A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis. Gastroenterology 133 (2007) 1414-1422
23. Oren R., Arber N., Odes S., et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110 (1996) 1416-1421
24. Levine J.S., and Burakoff R. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts. Inflamm Bowel Dis 13 (2007) 1293-1298
25. Berg D.F., Bahadursingh A.M., Kaminski D.L., and Longo W.E. Acute surgical emergencies in inflammatory bowel disease. Am J Surg 184 (2002) 45-51
26. Larson D.W., and Pemberton J.H. Current concepts and controversies in surgery for IBD. Gastroenterology 126 (2004) 1611-1619
27. Itzkowitz S.H., and Present D.H. Consensus conference. Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 314-321
28. Thirlby R.C., Sobrino M.A., and Randall J.B. The long-term benefit of surgery on health-related quality of life in patients with inflammatory bowel disease. Arch Surg 136 (2001) 521-527
29. Dahlstrom K., Edsbacker S., and Kallen A. Rectal pharmacokinetics of budesonide. Eur J Clin Pharmacol 49 (1996) 293-298
30. Gionchetti P., Rizzello F., Venturi A., et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 41 (1998) 93-97